IDEAS home Printed from https://ideas.repec.org/a/eee/respol/v32y2003i10p1865-1879.html
   My bibliography  Save this article

Institutional frameworks and innovation in the German and UK pharmaceutical industry

Author

Listed:
  • Casper, Steven
  • Matraves, Catherine

Abstract

No abstract is available for this item.

Suggested Citation

  • Casper, Steven & Matraves, Catherine, 2003. "Institutional frameworks and innovation in the German and UK pharmaceutical industry," Research Policy, Elsevier, vol. 32(10), pages 1865-1879, December.
    • Handle: RePEc:eee:respol:v:32:y:2003:i:10:p:1865-1879
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0048-7333(03)00082-9
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Henderson, Rebecca., 1994. "The evolution of integrative capability : innovation in cardiovascular drug discovery," Working papers 3711-94., Massachusetts Institute of Technology (MIT), Sloan School of Management.
    2. Zucker, Lynne G. & Darby, Michael R., 1997. "Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm," Research Policy, Elsevier, vol. 26(4-5), pages 429-446, December.
    3. Christel Lane, 1995. "Industry and Society in Europe," Books, Edward Elgar Publishing, number 272.
    4. Masahiko Aoki, 2013. "Toward an Economic Model of the Japanese Firm," Chapters, in: Comparative Institutional Analysis, chapter 18, pages 315-341, Edward Elgar Publishing.
    5. Patel, Pari, 1995. "Localised Production of Technology for Global Markets," Cambridge Journal of Economics, Oxford University Press, vol. 19(1), pages 141-153, February.
    6. Henry Grabowski & John Vernon, 1990. "A New Look at the Returns and Risks to Pharmaceutical R&D," Management Science, INFORMS, vol. 36(7), pages 804-821, July.
    7. Matraves, Catherine, 1999. "Market Structure, R&D and Advertising in the Pharmaceutical Industry," Journal of Industrial Economics, Wiley Blackwell, vol. 47(2), pages 169-194, June.
    8. Mowery,David C. & Nelson,Richard R. (ed.), 1999. "Sources of Industrial Leadership," Cambridge Books, Cambridge University Press, number 9780521645201.
    9. Grabowski, Henry G. & Vernon, John M., 1994. "Returns to R&D on new drug introductions in the 1980s," Journal of Health Economics, Elsevier, vol. 13(4), pages 383-406.
    10. Steven Casper & Mark Lehrer & David Soskice, 1999. "Can High-technology Industries Prosper in Germany? Institutional Frameworks and the Evolution of the German Software and Biotechnology Industries," Industry and Innovation, Taylor & Francis Journals, vol. 6(1), pages 5-24.
    11. Rebecca Henderson & Iain Cockburn, 1996. "Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery," RAND Journal of Economics, The RAND Corporation, vol. 27(1), pages 32-59, Spring.
    12. Steven Casper & Hannah Kettler, 2001. "National Institutional Frameworks And The Hybridization Of Entrepreneurial Business Models: The German And Uk Biotechnology Sectors," Industry and Innovation, Taylor & Francis Journals, vol. 8(1), pages 5-30.
    13. Mark Lehrer, 1997. "German Industrial Strategy in Turbulence: Corporate Governance and Managerial Hierarchies in Lufthansa," Industry and Innovation, Taylor & Francis Journals, vol. 4(1), pages 115-140.
    14. Penan, H., 1996. "R & D strategy in a techno-economic network: Alzheimer's disease therapeutic strategies," Research Policy, Elsevier, vol. 25(3), pages 337-358, May.
    15. Catherine Matraves, 1999. "Market Structure, R&D and Advertising in the Pharmaceutical Industry," Journal of Industrial Economics, Wiley Blackwell, vol. 47(2), pages 169-194, June.
    16. Gambardella, Alfonso & Orsenigo, Luigi & Pammolli, Fabio, 2000. "Global Competitiveness in Pharmaceuticals: A European Perspective," MPRA Paper 15965, University Library of Munich, Germany.
    17. Nightingale, Paul, 2000. "Economies of Scale in Experimentation: Knowledge and Technology in Pharmaceutical R&D," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 9(2), pages 315-359, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Steven Casper & Catherine Matraves, 1997. "Corporate Governance and Firm Strategy in the Pharmaceutical Industry," CIG Working Papers FS IV 97-20, Wissenschaftszentrum Berlin (WZB), Research Unit: Competition and Innovation (CIG).
    2. Casper, Steven & Whitley, Richard, 2004. "Managing competences in entrepreneurial technology firms: a comparative institutional analysis of Germany, Sweden and the UK," Research Policy, Elsevier, vol. 33(1), pages 89-106, January.
    3. Gilsing, Victor & Nooteboom, Bart, 2006. "Exploration and exploitation in innovation systems: The case of pharmaceutical biotechnology," Research Policy, Elsevier, vol. 35(1), pages 1-23, February.
    4. Stefano Brusoni & Paola Criscuolo & Aldo Geuna, 2005. "The knowledge bases of the world's largest pharmaceutical groups: what do patent citations to non-patent literature reveal?," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 14(5), pages 395-415.
    5. Gianluca Baio & Laura Magazzini & Antonio Nicita & Fabio Pammolli & Massimo Riccaboni, 2003. "Il Decreto DL 15/04/2002, n. 63 sul Contenimento della Spesa Farmaceutica - Impatto sull'Industria e Distorsioni nel Funzionamento del Mercato," Working Papers CERM 0-2003, Competitività, Regole, Mercati (CERM).
    6. Klaus Brockhoff, 2006. "Technologischer Wandel und Corporate Governance," Schmalenbach Journal of Business Research, Springer, vol. 58(54), pages 7-31, January.
    7. Bottazzi, Giulio & Dosi, Giovanni & Lippi, Marco & Pammolli, Fabio & Riccaboni, Massimo, 2001. "Innovation and corporate growth in the evolution of the drug industry," International Journal of Industrial Organization, Elsevier, vol. 19(7), pages 1161-1187, July.
    8. Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni, 2013. "Technological Regimes and Demand Structure in the Evolution of the Pharmaceutical Industry," Economic Complexity and Evolution, in: Andreas Pyka & Esben Sloth Andersen (ed.), Long Term Economic Development, edition 127, pages 61-94, Springer.
    9. Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680.
    10. Lehrer, Mark & Asakawa, Kazuhiro, 2004. "Rethinking the public sector: idiosyncrasies of biotechnology commercialization as motors of national R&D reform in Germany and Japan," Research Policy, Elsevier, vol. 33(6-7), pages 921-938, September.
    11. Whitley, Richard, 2003. "Competition and pluralism in the public sciences: the impact of institutional frameworks on the organisation of academic science," Research Policy, Elsevier, vol. 32(6), pages 1015-1029, June.
    12. Jacqueline Senker, 2006. "Biotechnology Alliances in the European Pharmaceutical Industry: Past, Present and Future," SPRU Working Paper Series 137, SPRU - Science Policy Research Unit, University of Sussex Business School.
    13. Luigi Orsenigo & Fabio Pammolli & Massimo Riccaboni, 1999. "Competencies, Technological Change and Network Dynamics. The case of the bio-pharmaceutical industry," LEM Papers Series 1999/13, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
    14. Rothaermel, Frank T. & Thursby, Marie, 2007. "The nanotech versus the biotech revolution: Sources of productivity in incumbent firm research," Research Policy, Elsevier, vol. 36(6), pages 832-849, July.
    15. N. Lacetera & L. Zirulia, 2008. "Knowledge Spillovers, Competition, and R&D Incentive Contracts," Working Papers 624, Dipartimento Scienze Economiche, Universita' di Bologna.
    16. Catherine Matraves, 1998. "Market Structure, R&D and Advertising in the Pharmaceutical Industry," CIG Working Papers FS IV 98-17, Wissenschaftszentrum Berlin (WZB), Research Unit: Competition and Innovation (CIG).
    17. Mahlich, Jörg C. & Yurtoglu, Burcin, 2011. "Intangibles Kapital und Rentabilität in der Pharmaindustrie," Die Unternehmung - Swiss Journal of Business Research and Practice, Nomos Verlagsgesellschaft mbH & Co. KG, vol. 65(1), pages 32-49.
    18. Lehrer, Mark & Nell, Phillip & Gärber, Lisa, 2007. "A National Systems View of University Development: Towards a Broadened Perspective on the Entrepreneurial University Based on the German and US Experience," Kiel Working Papers 1370, Kiel Institute for the World Economy (IfW Kiel).
    19. Havas, Attila, 2010. "Diversity in firms’ innovation strategies and activities: Main findings of interviews and implications in the context of the Hungarian national," MPRA Paper 55852, University Library of Munich, Germany.
    20. Sternitzke, Christian, 2010. "Knowledge sources, patent protection, and commercialization of pharmaceutical innovations," Research Policy, Elsevier, vol. 39(6), pages 810-821, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:respol:v:32:y:2003:i:10:p:1865-1879. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/locate/respol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.